What is it about?
Effective anti‐respiratory syncytial virus (RSV) agents are still not available for clinical use. We have investigated the effects of late therapeutic intervention (clinical treatment senario) with a novel inhaled RSV polymerase inhibitor, PC786, on RSV infection in human airway epithelium. Late therapeutic intervention with the RSV polymerase inhibitor, PC786, reduced the viral burden quickly in human airway epithelium. Thus, PC786 demonstrates the potential to be an effective therapeutic agent to treat active RSV infection.
Featured Image
Why is it important?
Effective anti‐respiratory syncytial virus (RSV) agents are still not available for clinical use and major recent approch is virus entry inhibition for prophylactic use. This new approach with polymerase inhibitor enables to inhibit RSV replication even after virus inbfection is established. In addition, this molecule is optimised for inhalation, leading limited systemic efefcts and high local exposure for more potent anti-viral effect and less mutation induction.
Perspectives
We set up 3D air-liquid interfecase cultured airway epithelial cells as more translational model as RSV does not replicate well in animals as this is human respiratory virus. This system is useful for different intervention (inhalation, oral mimic, daily treatment, biomarker analysis etc) .
Dr Kazuhiro Ito
kaz@pulmocide.com
Read the Original
This page is a summary of: Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium, British Journal of Pharmacology, May 2018, Wiley,
DOI: 10.1111/bph.14221.
You can read the full text:
Contributors
The following have contributed to this page
